BIO-TECHNE Corp (TECH) Insider Transactions
Over the last 12 months, 15 BIO-TECHNE Corp (TECH) insiders filed 119 SEC Form 4 transactions — $0 in open-market purchases ( 0 distinct buyers) and $2.4M in open-market sales. 0% of all transactions were executed under a pre-scheduled Rule 10b5-1 trading plan.
- $0Open-market buys (1y)
- $2.4MOpen-market sells (1y)
- 15Distinct insiders
- 119Transactions filed
- 0%Under Rule 10b5-1 plan
- 2026-06-02Latest filing
Recent Form 4 Filings Most recent 50 of 119 (1-year window)
Each row is a single Form 4 filing event for TECH, sourced directly from SEC EDGAR. The Type column classifies the SEC transaction code into Buy / Sell / Grant / Exercise / Other; the 10b5-1 badge marks trades executed under a pre-scheduled SEC Rule 10b5-1 plan.
| Date | Insider | Title | Type | SEC Code | Value | Shares | Price |
|---|---|---|---|---|---|---|---|
| 2026-06-02 | Crouse Steven C. | President - Diag & Spatial Bi | Exercise | M | $0 | 600 | — |
| 2026-06-02 | Crouse Steven C. | President - Diag & Spatial Bi | Exercise | M | $0 | 600 | $0.00 |
| 2026-06-02 | Crouse Steven C. | President - Diag & Spatial Bi | Other | F | $10.8K | 216 | $49.77 |
| 2026-05-08 | Herr Amy E. | — | Exercise | M | $315.9K | 6,636 | $47.60 |
| 2026-05-08 | Herr Amy E. | — | Exercise | M | $0 | 6,636 | $0.00 |
| 2026-05-08 | Herr Amy E. | — | Sell | S | $320.4K | 6,636 | $48.28 |
| 2026-05-05 | Hippel James | CFO | Exercise | M | $3.0M | 62,000 | $47.60 |
| 2026-05-05 | Hippel James | CFO | Exercise | M | $0 | 62,000 | $0.00 |
| 2026-05-05 | Bohnen Shane | SVP - General Counsel | Exercise | M | $399.8K | 8,400 | $47.60 |
| 2026-05-05 | Bohnen Shane | SVP - General Counsel | Exercise | M | $0 | 8,400 | $0.00 |
| 2026-05-05 | Kelderman Kim | Chief Executive Officer | Exercise | M | $1.3M | 26,692 | $47.60 |
| 2026-05-05 | Kelderman Kim | Chief Executive Officer | Exercise | M | $0 | 26,692 | $0.00 |
| 2026-05-05 | Hippel James | CFO | Other | F | $3.2M | 56,955 | $56.68 |
| 2026-05-05 | Bohnen Shane | SVP - General Counsel | Other | F | $399.9K | 7,055 | $56.68 |
| 2026-05-05 | Kelderman Kim | Chief Executive Officer | Other | F | $1.4M | 23,951 | $56.68 |
| 2026-05-01 | Crouse Steven C. | President - Diag & Spatial Bi | Exercise | M | $0 | 794 | — |
| 2026-05-01 | Crouse Steven C. | President - Diag & Spatial Bi | Exercise | M | $0 | 794 | $0.00 |
| 2026-05-01 | Crouse Steven C. | President - Diag & Spatial Bi | Other | F | $17.1K | 311 | $55.02 |
| 2026-04-22 | Kelderman Kim | Chief Executive Officer | Exercise | M | $0 | 11,344 | $0.00 |
| 2026-04-22 | Kelderman Kim | Chief Executive Officer | Exercise | M | $0 | 11,344 | $0.00 |
| 2026-04-22 | Hippel James | CFO | Exercise | M | $0 | 62,000 | $0.00 |
| 2026-04-22 | Hippel James | CFO | Exercise | M | $0 | 62,000 | $0.00 |
| 2026-04-22 | Kelderman Kim | Chief Executive Officer | Other | F | $79.8K | 1,363 | $58.58 |
| 2026-04-22 | Hippel James | CFO | Other | F | $3.3M | 56,097 | $58.58 |
| 2026-04-14 | Kelderman Kim | Chief Executive Officer | Exercise | M | $0 | 36,500 | $0.00 |
| 2026-04-14 | Kelderman Kim | Chief Executive Officer | Exercise | M | $0 | 36,500 | $0.00 |
| 2026-04-14 | Kelderman Kim | Chief Executive Officer | Other | F | $1.9M | 32,088 | $58.66 |
| 2026-04-03 | Bohnen Shane | SVP - General Counsel | Exercise | M | $0 | 2,259 | $0.00 |
| 2026-04-03 | Bohnen Shane | SVP - General Counsel | Exercise | M | $0 | 2,259 | $0.00 |
| 2026-04-03 | Bohnen Shane | SVP - General Counsel | Other | F | $39.3K | 740 | $53.13 |
| 2026-03-02 | Crouse Steven C. | President - Diag & Spatial Bi | Grant | — | $0 | 2,387 | $0.00 |
| 2026-03-02 | Crouse Steven C. | President - Diag & Spatial Bi | Grant | — | $0 | 735 | $0.00 |
| 2026-03-02 | Crouse Steven C. | President - Diag & Spatial Bi | Grant | — | $0 | 1,911 | $0.00 |
| 2026-02-17 | Herr Amy E. | — | Sell | — | $116.8K | 1,976 | $59.10 |
| 2026-02-03 | Herr Amy E. | — | Grant | — | $0 | 38 | $0.00 |
| 2026-02-03 | Herr Amy E. | — | Grant | — | $1.0K | 16 | $64.63 |
| 2026-02-03 | Herr Amy E. | — | Grant | — | $0 | 38 | $0.00 |
| 2026-02-01 | McManus Matthew | President - Diag & Spatial Bio | Grant | — | $0 | 4,621 | $0.00 |
| 2026-02-01 | McManus Matthew | President - Diag & Spatial Bio | Grant | — | $106.7K | 1,665 | $64.09 |
| 2026-02-01 | McManus Matthew | President - Diag & Spatial Bio | Grant | — | $0 | 4,621 | $0.00 |
| 2025-11-03 | Kelderman Kim | Chief Executive Officer | Grant | — | $144.1K | 2,303 | $62.57 |
| 2025-11-03 | Hippel James | CFO | Grant | — | $0 | 13,159 | $0.00 |
| 2025-11-03 | Hippel James | CFO | Grant | — | $0 | 11,545 | $0.00 |
| 2025-11-03 | Hippel James | CFO | Grant | — | $742.4K | 11,865 | $62.57 |
| 2025-11-03 | Hippel James | CFO | Grant | — | $0 | 13,159 | $0.00 |
| 2025-11-03 | Hippel James | CFO | Grant | — | $0 | 11,545 | $0.00 |
| 2025-11-03 | Geist William | PRESIDENT, PROTEIN SCIENCES | Grant | — | $0 | 9,911 | $0.00 |
| 2025-11-03 | Geist William | PRESIDENT, PROTEIN SCIENCES | Grant | — | $282.8K | 4,520 | $62.57 |
| 2025-11-03 | Geist William | PRESIDENT, PROTEIN SCIENCES | Grant | — | $0 | 9,911 | $0.00 |
| 2025-10-30 | Bushman Julie L | — | Grant | — | $0 | 1,640 | $0.00 |
Showing the most recent 50 of 119 transactions. For the full 1-year history with sorting, filtering, and cross-ticker industry context, open the full insider transactions drilldown.
Methodology & FAQ
How We Track TECH Insider Transactions
Form 4 disclosures are sourced directly from SEC EDGAR and re-ingested on every pipeline cycle. A complete description of transaction-code handling, the open-market vs grant distinction, and the Rule 10b5-1 plan-reference heuristic is documented in the Methodology.
What is an SEC Form 4 filing for BIO-TECHNE Corp?
Form 4 is a transaction-level disclosure that corporate insiders — officers, directors, and beneficial owners of more than 10% of a registered class of equity securities — must file with the SEC within two business days of any change in their beneficial ownership of BIO-TECHNE Corp (TECH) shares.
What is a Rule 10b5-1 trading plan?
Rule 10b5-1 is an SEC rule that lets insiders schedule trades in advance under a written plan, providing an affirmative defense against insider-trading allegations as long as the plan was adopted in good faith and not while in possession of material non-public information. Form 4 rows marked "10b5-1" on this page indicate the underlying trade was executed under such a plan; rows without the badge are discretionary or did not reference a plan in the Form 4 footnotes.
How is "insider buying" different from a stock grant or option exercise?
An insider buy (SEC transaction code P) is an open-market purchase of BIO-TECHNE Corp (TECH) stock executed at the prevailing market price using the insider's personal capital. Stock grants (code A) and option exercises (code M) are compensation events, not directional trades; they are tracked separately and excluded from the "conviction" signal because they are not discretionary purchases.
How recent is the data?
Form 4 transactions are typically reported within two business days of execution. Pactolio re-ingests the EDGAR feed on a nightly cycle and reflects new filings on the next ingest run, typically within 24 hours of EDGAR acceptance. The table on this page covers the most recent 1-year window.